Atavistik Bio, a clinical-stage biotechnology company developing the next generation of oral selective allosteric therapeutics for the treatment of rare haematological diseases, has announced it has joined the cure HHT clinical trial network (CTN) to support the clinical development of ATV-1601, an investigational oral allosteric AKT1-selective inhibitor for the treatment of hereditary haemorrhagic telangiectasia (HHT).
Joining the Cure HHT CTN coincides with activation of the first clinical site in Atavistik Bio’s Harmony-HHT phase 1/2 study at Massachusetts General Hospital (MGH), marking an important milestone in the advancement of the clinical programme.
Through participation in the cure HHT CTN, Atavistik Bio will work closely with cure HHT to leverage the organisation’s trial-qualified centres of excellence, established patient and clinician community, and extensive HHT-specific clinical and regulatory expertise to support execution of the Harmony-HHT study. The cure HHT CTN is a first-of-its-kind partnership platform designed to accelerate development of new therapies for HHT.
Through the collaboration, Atavistik Bio and cure HHT will work together on patient education, community outreach, clinical trial awareness initiatives and engagement activities designed to help connect eligible individuals with the Harmony-HHT study.
The phase 1/2 clinical trial is a proof-of-concept study designed to evaluate the safety and efficacy of ATV-1601 for individuals with moderate to severe HHT.
